Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Rome IV Diagnostic Criteria for Cannabinoid Hyperemesis Syndrome (CHS)

    Official Rome IV criteria for the diagnosis of cannabinoid hyperemesis syndrome.

    INSTRUCTIONS

    Use in patients with symptoms suggestive of cannabinoid hyperemesis syndrome (CHS) such as stereotypical episodes of vomiting, resembling cyclic vomiting syndrome (CVS), for at least the past 6 months, in the setting of prolonged cannabis use.

    Patients with any of the following features must be evaluated clinically for other diagnoses even though CHS may be present:

    • Signs or symptoms of GI bleeding.

    • Unexplained iron deficiency anemia.

    • Unintentional weight loss.

    • Palpable abdominal mass or lymphadenopathy on exam.

    • Family history of GI cancer and no recent upper endoscopy.

    • Dysphagia.

    • Persistent vomiting.

    • Neurologic symptoms.

    When to Use
    Pearls/Pitfalls
    Why Use

    Patients presenting with stereotypical episodes of vomiting suggestive of cannabinoid hyperemesis syndrome (CHS) with symptoms for at least the past 6 months, in the setting of prolonged cannabis use. The diagnosis of CHS should be made by clinical history, physical examination, and minimal laboratory tests, which should include a drug screen.

    • Suspect CHS in patients who present with symptoms consistent with cyclic vomiting syndrome (CVS).

    • A diagnosis of CHS can only be made after a careful diagnostic workup reveals no evidence of organic, systemic, or metabolic disease to explain the symptoms. Workup may include a drug screen if cannabis use is denied.

    • CHS may be associated with prolonged hot baths or showers.

    • While cannabis use may temporarily improve nausea and vomiting, complete relief is achieved only after sustained cessation of cannabis use (e.g. for at least the duration of 2-3 episodes).

    • CHS and CVS have similar clinical presentations. Therefore, patients who get sustained relief of symptoms after stopping cannabis have CHS. Patients who continue to have symptoms after stopping cannabis for an extended period of time have CVS. Cannabis may exacerbate CVS symptoms.

    • Helps to make a diagnosis of cannabinoid hyperemesis syndrome when appropriate workup of upper GI symptoms is nondiagnostic.

    • Helps to distinguish symptoms from other functional disorders of nausea and vomiting, such as cyclic vomiting syndrome and chronic nausea and vomiting syndrome.

    • Helps to guide management of vomiting symptoms, namely cessation of cannabis use.

    Must have the following:

    For 3 months prior with symptom onset ≥6 months ago

    Diagnostic Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Douglas Drossman

    About the Creator

    Douglas Drossman, MD, is professor emeritus of medicine and psychiatry at the University of North Carolina School of Medicine. He is founder, President Emeritus and Chief of Operations of the Rome Foundation. He is also the founder of the Drossman Center for the Education and Practice of Biopsychosocial Care and Drossman Consulting, LLC. Dr. Drossman has written over 500 articles and book chapters, has published two books, a GI procedure manual and a textbook of functional GI disorders (Rome I-IV), and serves on six editorial and advisory boards.

    To view Dr. Douglas Drossman's publications, visit PubMed

    Dr. Lin Chang

    About the Creator

    Lin Chang, MD is responsible for the oversight and coordination of the Rome IV calculators on MDCalc. She is a Professor of Medicine at the Vatche and Tamar Manoukian Division of Digestive Diseases at UCLA and is a member of the Rome Foundation Board of Directors.

    To view Dr. Lin Chang's publications, visit PubMed

    The Rome Foundation

    About the Creator

    The Rome Foundation is an independent not for profit 501(c) 3 organization that provides support for activities designed to create scientific data and educational information to assist in the diagnosis and treatment of Disorders of Gut-Brain Interaction (DGBI), also known as functional gastrointestinal (GI) disorders. Their mission is to improve the lives of people with DGBI. Over the last 3 decades, the Rome organization has sought to legitimize and update our knowledge of the DGBIs. This has been accomplished by bringing together scientists and clinicians from around the world to classify and critically appraise the science of GI function and dysfunction. This knowledge permits clinical scientists to make recommendations for diagnosis and treatment that can be applied in research and clinical practice. Diagnosis is based on the use of symptom-based criteria which are used in clinical trials and daily practice. The list of Rome IV categories and the Chair and Co-Chair of each chapter committee are listed below.

    Committees Chair Co-Chair
    Esophageal Disorders Ronnie Fass, MD John Pandolfino, MD
    Gastroduodenal Disorders Nicholas J. Talley, MD, PhD, FRACP Vincenzo Stanghellini, MD
    Bowel Disorders Fermin Mearin, MD Brian Lacy, MD, PhD
    Gallbladder and Sphincter of Oddi Disorders Grace Elta, MD Peter Cotton, MD
    Centrally Mediated Disorders of Gastrointestinal Pain Peter J. Whorwell, MD Laurie Keefer, PhD
    Anorectal Disorders Adil E. Bharucha, MD, MBBS Satish S. C. Rao, MD, PhD, FRCP
    Childhood Functional Gastrointestinal Disorders: Neonate/Toddler Sam Nurko, MD Marc A. Benninga, MD
    Childhood Functional Gastrointestinal Disorders: Child/Adolescent Carlo Di Lorenzo, MD Jeffrey S. Hyams, MD

    Rome IV Diagnostic Criteria Chapters, Chairs and Co-Chairs

    Rome IV Editorial Board: Douglas A. Drossman, MD, Senior Editor, Lin Chang, MD, William D. Chey, MD, John Kellow, MD, Jan Tack, MD, PhD, and William E. Whitehead, PhD.

    To view The Rome Foundation's publications, visit PubMed

    Content Contributors
    • David Cangemi, MD
    Reviewed By
    • William D. Chey, MD, AGAF, FACG, FACP
    About the Creator
    Dr. Douglas Drossman
    Dr. Lin Chang
    The Rome Foundation
    Content Contributors
    • David Cangemi, MD
    Reviewed By
    • William D. Chey, MD, AGAF, FACG, FACP